Ocular Therapeutix, Inc. (OCUL) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $9.16: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.4/10 and A.R:R 11.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum.
Ocular Therapeutix is a clinical-stage biopharmaceutical company developing hydrogel-based ophthalmic drug delivery using its ELUTYX technology. Its sole commercial product is DEXTENZA (corticosteroid intracanalicular insert for ocular inflammation/pain and allergic... Read more
Sell if holding. Engine safety override at $9.16: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.4/10 and A.R:R 11.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 57. Score 3.4/10, high confidence.
Passes 4/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductDEXTENZA10-K Item 1A: 'Although we expect to continue to generate revenue from sales of DEXTENZA, we expect to continue to incur significant expenses and operating losses over the next several years'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
6 floor-breakers·1 ceiling hit
Revenue shrinking — -22.4% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.16: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.4/10 and A.R:R 11.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 57. Prior stop was $8.52. Score 3.4/10, high confidence.
Take-profit target: $22.62 (+146.8% upside). Prior stop was $8.52. Stop-loss: $8.52.
Concentration risk — Product: DEXTENZA; Quality below floor (1.9 < 4.0).
Ocular Therapeutix, Inc. trades at a P/E of N/A (forward -7.3). TrendMatrix value score: 5.4/10. Verdict: Sell.
18 analysts cover OCUL with a consensus score of 4.3/5. Average price target: $26.
What does Ocular Therapeutix, Inc. do?Ocular Therapeutix is a clinical-stage biopharmaceutical company developing hydrogel-based ophthalmic drug delivery...
Ocular Therapeutix is a clinical-stage biopharmaceutical company developing hydrogel-based ophthalmic drug delivery using its ELUTYX technology. Its sole commercial product is DEXTENZA (corticosteroid intracanalicular insert for ocular inflammation/pain and allergic conjunctivitis), while its lead pipeline asset AXPAXLI (axitinib for wet AMD and diabetic retinal disease) is in Phase 3 registrational trials.